8.56

1.30% 0.11

After Hours: 8.56

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $8.56, with a volume of 348.03K. It is up +1.30% in the last 24 hours and up +9.04% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Previous Close:

$8.45

Open:

$8.6

24h Volume:

348.03K

Relative Volume:

0.35

Market Cap:

$192.97M

Revenue:

$146.07M

Net Income/Loss:

$-196.04M

P/E Ratio:

-0.515

EPS:

-16.621

Net Cash Flow:

$-75.37M

1W Performance:

+18.07%

1M Performance:

+9.04%

6M Performance:

+43.87%

1Y Performance:

+100.94%

1-Day Range:

$8.40

$8.81

1-Week Range:

$7.19

$8.87

52-Week Range:

$3.6503

$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

228

Twitter

@Karyopharm

Next Earnings Date

2024-11-05

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	8.56	190.49M	146.07M	-196.04M	-75.37M	-16.62
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-26	Initiated	Rodman & Renshaw	Buy
Feb-05-26	Initiated	Cantor Fitzgerald	Overweight
Oct-13-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

Apr 15, 2026

Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN

Apr 15, 2026

KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN

Apr 15, 2026

Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN

Apr 15, 2026

Apr 14, 2026

Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN

Apr 14, 2026

Apr 13, 2026

Karyopharm Therapeutics (KPTI) affiliated managers report 1.9%–2.3% stakes - Stock Titan

Apr 13, 2026

[ARS] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan

Apr 13, 2026

Karyopharm (KPTI) seeks approval for director slate and larger equity plans - Stock Titan

Apr 13, 2026

Gains Report: Can Karyopharm Therapeutics Inc disrupt its industry2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | KPTI Stock News - GuruFocus

Apr 12, 2026

Apr 10, 2026

Portfolio Update: Will Karyopharm Therapeutics Inc stock benefit from M A2026 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

Quarterly Earnings: How sensitive is Karyopharm Therapeutics Inc to inflationPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating - Moomoo

Apr 07, 2026

Apr 06, 2026

Dip Buying: Is Karyopharm Therapeutics Inc attractive for institutional investors2026 Update & Growth Oriented Trading Recommendations - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 03, 2026

Apr 02, 2026

RA Capital (NASDAQ: KPTI) and partners report 9.99% stake in Karyopharm - Stock Titan

Apr 02, 2026

Commodore Group discloses 1.95M KPTI stake; 19,618,032 shares O/S - Stock Titan

Apr 02, 2026

Karyopharm Therapeutics Inc. R (25K0.DU) insider ownership and holdings - Yahoo Finance Australia

Apr 02, 2026

Mar 31, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March - MarketBeat

Mar 31, 2026

Will Karyopharm Therapeutics Inc benefit from green energy policiesInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Piper Sandler Lowers Price Target for Karyopharm Therapeutics (K - gurufocus.com

Mar 30, 2026

Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Mar 30, 2026

Karyopharm stock price target cut to $8 by Piper Sandler on trial results - ca.investing.com

Mar 30, 2026

Mar 27, 2026